Tacalyx is a biotech company that develops therapies that target cancer by focusing on tumor-associated carbohydrate antigens.
Tacalyx has raised $12.9M in total funding. The most recent round was Seed. The last funding was announced in April 2026.
Tacalyx's investors include HTGF (High-Tech Gruenderfonds), Kurma Partners, Eurazeo, Boehringer Ingelheim Venture Fund, Idinvest Partners.
Tacalyx is headquartered in Berlin, Germany.
Tacalyx is a biotech company that develops therapies that target cancer by focusing on tumor-associated carbohydrate antigens.
Tacalyx is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tacalyx — Funding & Investors." VCBacked, April 29, 2026, https://www.vcbacked.co/company/tacalyx. Accessed July 19, 2026.
VCBacked. (2026). Tacalyx — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/tacalyx
{{cite web |title=Tacalyx — Funding & Investors |url=https://www.vcbacked.co/company/tacalyx |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated